We use cookies. Find out more about it here. By continuing to browse this site you are agreeing to our use of cookies.
#alert
Back to search results
New

Associate Director, Strategy & Portfolio Analytics

Alnylam Pharmaceuticals
United States, Massachusetts, Cambridge
675 West Kendall Street (Show on map)
Jan 23, 2025

This role is considered Hybrid.

Overview

The Associate Director, Strategy and Portfolio Analytics will report to the Senior Director, Portfolio Analytics and will aid in building and advancing our analytical capabilities for analyzing our pipeline of potential drugs ranging from pre-clinical assets through registration and assisting asset teams with fit-for-purpose analyses of alternative clinical development paths and life cycle management strategies. Familiarity with multiple portfolio and asset analytical frameworks, as well as emerging analytical tools and capabilities, is required. This role will also support the Enterprise Strategy Team with its strategic projects, examples of which may include refreshing the corporate strategy or disease area strategy development.

The role will require an ability to multi-task, prioritize multiple initiatives, and develop solutions where blueprints may not exist. This individual will work cross-functionally as a trusted partner to leadership within teams and line functions. Success will require a strong ability to translate analytics into insights in a way that engages and influences leaders to focus on business needs and key strategic questions.

Efforts to advance our portfolio analytical capabilities should include consideration for leveraging enterprise tools, adding appropriate AI capabilities, and building standardized models and tools with the goal of providing data and insights that inform strategic portfolio decisions. Insights generated by the Portfolio Analytics Team will be an important input to Alnylam's strategies at an enterprise, disease area, and asset level.

The Associate Director, Strategy & Portfolio Analytics will also be responsible for identifying and evaluating relevant data and analytics vendors, monitoring emerging vendor capabilities, and managing vendor relationships, where appropriate.

Given the rapid growth and breadth of our portfolio, the ideal candidate must be able to productively work within an uncertain and context shifting environment, work effectively in a matrix organization and with multiple cross-functional teams, and be able to pivot quickly in response to rapidly changing business conditions. The ability to think creatively, minimize process, drive data and analytics to implications, and rapidly move from idea creation to tangible plans will be critical to success.

Key Responsibilities

  • Build and advance our portfolio analytic capabilities to successfully integrate our scientific approach, our development, commercial, and financial forecasts, and competitive landscape analyses to generate actionable insights and inform critical strategic decisions at the enterprise, disease area, and asset level
  • Assist asset teams with fit-for-purpose analyses of alternative clinical development paths and life cycle management strategies
  • Support enterprise strategy projects by conducting strategic analyses, developing competitive landscape assessments, and defining and evaluating scenarios that will impact Alnylam's future
  • Assess new and emerging analytical tools and methodologies, including how best to leverage AI capabilities and incorporate these capabilities into our analytical processes and toolkit
  • Refine our analytical processes to improve efficiency, drive focus toward higher-order analyses, and standardize analytical output
  • Demonstrate strong stakeholder management and influencing skills and translate analytics into dialogue to address business issues and inform strategic decisions
  • Work cross-functionally to improve quality of the data inputs that ultimately drive the portfolio analysis insight and strategy recommendations
  • Cultivate and maintain strong cross-functional relationships and lead via influence within a globally matrixed organization and with adherence to our company values and culture

Qualifications

  • Must have 7+ years' experience in portfolio analytics and/or corporate strategy roles with a biopharma having over 10 clinical assets with different disease prevalences across more than 3 disease areas
  • MBA and/or MS Science, Data Science, or Data Analytics
  • Strong understanding of drug development, including experience with clinical development paths, regulatory hurdles, and key commercial inputs, including pricing and market access
  • Demonstrated ability to conduct analyses, present outputs, and translate analytics into strategic insights that will inform decision-making and/or address business challenges
  • Proven ability to work with senior-level management and executive team
  • Strong understanding of financial statements
  • Strong leadership, problem solving, management, and communication skills
  • Excellent interpersonal skills and ability to work effectively across multiple functions
  • Self-starter who can manage through ambiguity, learn on the fly, handle multiple priorities and perform job responsibilities accurately while working in a high energy, deadline-driven, and fast-paced environment

About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.

>
Applied = 0

(web-6f6965f9bf-7hrd4)